The ERKSens project promoted by Renalyse, a Rovira i Virgili University (URV) spinoff, together with the Eurecat technology centre and the URV has received €1.3 million from the RETOS programme to bring a device for diagnosing and monitoring haemoglobin and potassium to the market in four years.
The funding is part grant and part soft loan. It will enable CreatSens Health, together with the URV through the Chemometrics, Qualimetry and Nanosensors research group and the Eurecat technology centre, to place on the market a double sensor for determining potassium and haemoglobin in patients with chronic disease.
The ERKSens project will make it possible to measure these key biomarkers at home to deliver an immediate response to serious problems which may occur in the chronically ill patient’s domestic setting. The two markers can warn about problems such as arrhythmias, anaemia, severe deficiencies and even cardiopulmonary diseases. The main advantage is being able to give a faster, more efficient and more personalised response in a chronic patient’s acute episodes.
